相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Prognostic factors for long-term infliximab treatment in Crohn's disease patients: a 20-year single centre experience
T. Billiet et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2016)
Relationship of Body Mass Index to Clinical Outcomes after Infliximab Therapy in Patients with Crohn's Disease
Peter Brown et al.
JOURNAL OF CROHNS & COLITIS (2016)
ORBIT (Outcome and Retention Rate of Biologic Treatments for Psoriasis): A retrospective observational study on biologic drug survival in daily practice
Eva Vilarrasa et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Development of the Lemann Index to Assess Digestive Tract Damage in Patients With Crohn's Disease
Benjamin Pariente et al.
GASTROENTEROLOGY (2015)
Factors Associated with Durable Response to Infliximab in Crohn's Disease 5 Years and Beyond: A Multicenter International Cohort
Pascal Juillerat et al.
INFLAMMATORY BOWEL DISEASES (2015)
Body Mass Index and Smoking Affect Thioguanine Nucleotide Levels in Inflammatory Bowel Disease
Shi Sum Poon et al.
JOURNAL OF CROHNS & COLITIS (2015)
The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease
Niels Vande Casteele et al.
GUT (2015)
Patient Factors That Increase Infliximab Clearance and Shorten Half-life in Inflammatory Bowel Disease: A Population Pharmacokinetic Study
Iris Dotan et al.
INFLAMMATORY BOWEL DISEASES (2014)
Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions
J. Spertino et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2014)
Does Smoking Influence Crohn's Disease in the Biologic Era? The TABACROHN Study
Tiago Nunes et al.
INFLAMMATORY BOWEL DISEASES (2013)
Increased Body Mass Index Is Associated with Earlier Time to Loss of Response to Infliximab in Patients with Inflammatory Bowel Disease
Jason W. Harper et al.
INFLAMMATORY BOWEL DISEASES (2013)
The Increasing Weight of Crohn's Disease Subjects in Clinical Trials: A Hypothesis-generatings Time-trend Analysis
Gordon W. Moran et al.
INFLAMMATORY BOWEL DISEASES (2013)
Body weight increment in patients treated with infliximab for plaque psoriasis
V. Florin et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
Body mass index influences the response to infliximab in ankylosing spondylitis
Sebastien Ottaviani et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Review article: loss of response to anti-TNF treatments in Crohn's disease
S. Ben-Horin et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Body Mass Index and Clinical Response to Infliximab in Rheumatoid Arthritis
Ruth Klaasen et al.
ARTHRITIS AND RHEUMATISM (2011)
Effect of Obesity on the Pharmacokinetics of Drugs in Humans
Michael J. Hanley et al.
CLINICAL PHARMACOKINETICS (2010)
Disability in Inflammatory Bowel Diseases: Developing ICF Core Sets for Patients with Inflammatory Bowel Diseases Based on the International Classification of Functioning, Disability, and Health
Laurent Peyrin-Biroulet et al.
INFLAMMATORY BOWEL DISEASES (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of Infliximab Therapy on Abdominal Fat and Metabolic Profile in Patients with Crohn's Disease
Erika Parmentier-Decrucq et al.
INFLAMMATORY BOWEL DISEASES (2009)
A Brief Report of the Epidemiology of Obesity in the Inflammatory Bowel Disease Population of Tayside, Scotland
Helen Steed et al.
OBESITY FACTS (2009)
Review: Predicting response to anti-TNF agents for the treatment of Crohn's disease
Corey A. Siegel et al.
Therapeutic Advances in Gastroenterology (2009)
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
Mark A. Ainsworth et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2008)
Neuropeptides, Mesenteric Fat, and Intestinal Inflammation
Iordanes Karagiannides et al.
NEURAL SIGNALING: OPPORTUNITIES FOR NOVEL DIAGNOSTIC APPROACHES AND THERAPIES (2008)
Measurement of Nutrition Status in Crohn's Disease Patients Receiving Infliximab Therapy
Dawn Wiese et al.
NUTRITION IN CLINICAL PRACTICE (2008)
Mesenteric fat in Crohn's disease: A pathogenetic hallmark or an innocent bystander?
Laurent Peyrin-Biroulet et al.
GUT (2007)
Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution
Annabel Kuek et al.
POSTGRADUATE MEDICAL JOURNAL (2007)
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications
J. Satsangi et al.
GUT (2006)
The impact of increased body mass index on the clinical course of Crohn's disease
DJ Hass et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2006)
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
F Baert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
SB Hanauer et al.
LANCET (2002)
Crohn's disease clinical course and severity in obese patients
A Blain et al.
CLINICAL NUTRITION (2002)
A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease
BG Feagan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
分享论文
